TY - JOUR
T1 - Efficacy and Safety of Intragastric Balloon (IGB) in Non-alcoholic Fatty Liver Disease (NAFLD)
T2 - a Comprehensive Review and Meta-analysis
AU - Chandan, Saurabh
AU - Mohan, Babu P.
AU - Khan, Shahab R.
AU - Facciorusso, Antonio
AU - Ramai, Daryl
AU - Kassab, Lena L.
AU - Bhogal, Neil
AU - Asokkumar, Ravishankar
AU - Lopez-Nava, Gortrand
AU - McDonough, Stephanie
AU - Adler, Douglas G.
N1 - Publisher Copyright:
© 2021, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2021/3
Y1 - 2021/3
N2 - Intragastric balloon (IGB) therapy has shown efficacy in weight loss but its role in NAFLD remains unknown. We conducted a systematic review and meta-analysis to evaluate the efficacy of IGB in NAFLD. Meta-analysis was performed to estimate the pooled proportion of patients with improvement in steatosis as determined by imaging and histology following IGB placement. Nine studies were included in our analysis. Four hundred forty-two IGBs were placed. Improvement in steatosis was seen in 79.2% of patients and NAS in 83.5% of patients, and HOMA-IR score improved in 64.5% of patients. A reduction in liver volume by CT scan was noticed in 93.9% of patients undergoing IGB placement. IGB is an effective and safe short-term therapeutic modality for patients with NAFLD.
AB - Intragastric balloon (IGB) therapy has shown efficacy in weight loss but its role in NAFLD remains unknown. We conducted a systematic review and meta-analysis to evaluate the efficacy of IGB in NAFLD. Meta-analysis was performed to estimate the pooled proportion of patients with improvement in steatosis as determined by imaging and histology following IGB placement. Nine studies were included in our analysis. Four hundred forty-two IGBs were placed. Improvement in steatosis was seen in 79.2% of patients and NAS in 83.5% of patients, and HOMA-IR score improved in 64.5% of patients. A reduction in liver volume by CT scan was noticed in 93.9% of patients undergoing IGB placement. IGB is an effective and safe short-term therapeutic modality for patients with NAFLD.
UR - http://www.scopus.com/inward/record.url?scp=85099042128&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099042128&partnerID=8YFLogxK
U2 - 10.1007/s11695-020-05084-0
DO - 10.1007/s11695-020-05084-0
M3 - Review article
C2 - 33409973
AN - SCOPUS:85099042128
SN - 0960-8923
VL - 31
SP - 1271
EP - 1279
JO - Obesity Surgery
JF - Obesity Surgery
IS - 3
ER -